Canadian Respiratory Journal / 2019 / Article / Tab 2

Research Article

Concomitant Interstitial Lung Disease with Psoriasis

Table 2

Demographic and clinical features of 21 ILD patients with psoriasis.

PatientAge/sexArthritisAutoimmune disease/markerPrior/concomitant immunosuppressantsClinical diagnosisRadiographic diagnosisILD stagePathologyOutcome

168/MNoSSA (+)NoIPFUIP pattern#LimitedNot obtainedSurvived at 3 months
266/MNoNoNoRBILD/DIPRBILD/DIP patternLimitedRBILD/DIP patternSurvived at 34 months
352/MYesPM/DM CRESTNoCTD-ILDNSIP patternLimitedOP/EP patternSurvived at 56 months
480/MNoNoNoCOPOP patternLimitedOP/EP patternSurvived at 13 months
578/MNoNoNoIPFUIP patternLimitedNot obtainedSurvived at 51 months
646/MYesNoMTX, etanerceptIPF/IgG4-related lung diseaseNSIP/OP patternLimitedNot obtainedSurvived at 11 months
758/FYesNoHydroxychloroquine sulfate, MTX, infliximabNSIPNSIP/OP patternLimitedNot obtainedSurvived at 3 months
876/MNoNoNoIPFUIP patternExtensiveNot obtainedUnknown
949/MNoNoNoIPFUIP patternLimitedNot obtainedSurvived at 23 months
1060/MNoANCA (+)NoCHPOP/HP patternExtensiveEarly UIP/OPSurvived at 8 months
1162/MNoNoNoNSIPNSIP patternExtensiveNot obtainedSurvived at 48 months
1281/FNoNo6-MPCOPNSIP patternLimitedNot obtainedDied at 13 months
1380/FNoANCA (+)AzathioprineIPFUIP patternLimitedNot obtainedSurvived at 1 month
1463/MNoNoNoIPFUIP patternLimitedNot obtainedSurvived at 46 months
1548/MNoNoNoIPFNSIP patternExtensiveNot obtainedSurvived at 18 months
1653/FNoNoNoMitral valve lung diseaseReticular and GGO in lung bases with innumerable small nodulesLimitedNot obtainedSurvived at 17 months
1767/MNoNoMTX, etanerceptIPFUIP patternExtensiveNot obtainedSurvived at 4 months
1862/FNoNoChemotherapy for breast cancerIPFUIP patternExtensiveNot obtainedSurvived at 12 months
1986/FNoNoNoIPFUIP patternExtensiveNot obtainedDied at 8 months
2079/MNoNoChemotherapy for lymphomaUnspecificMosaic attenuationLimitedNot obtainedSurvived at 53 months
2169/FYesNoMTX, etanercept sulfasalazineCHPHP patternLimitedNot obtainedSurvived at 4 months

ANA: antinuclear antibody, ANCA: antineutrophil cytoplasmic antibody, CHP: chronic hypersensitivity pneumonitis, COP: cryptogenic organizing pneumonia, CTD-ILD: connective tissue disease-associated interstitial lung disease, EP: eosinophilic pneumonia, F: female, GGO: ground glass opacities, HP: hypersensitivity pneumonitis, IPF: idiopathic pulmonary fibrosis, M: male, MP: mercaptpurine, MTX: methotrexate, NSIP: nonspecific interstitial pneumonia, OP: organizing pneumonia, PE: pulmonary embolus, PM/DM: polymyositis/dermatomyositis, RBILD/DIP: respiratory bronchiolitis-associated interstitial lung disease/desquamative interstitial pneumonia, SSA: SS-A antibody, and UIP: usual interstitial pneumonia. A staging system, originally proposed for ILD with systemic sclerosis, by Goh et al. [11]. Patient had a mild elevation of serum SS-A (1.20 AI) but lacked sicca symptom and other symptoms suggestive of underlying autoimmune disease (i.e., arthralgia, digital fissuring/ulceration, and Raynaud’s phenomenon). Patients had positivity of serum ANCA but lacked clinical symptom suggestive of underlying systemic vasculitis (i.e., skin rash, alveolar haemorrhage, and glomerulonephritis). #We defined both radiological “definitive UIP pattern” and “probable UIP pattern” as “UIP pattern” in the present study.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.